Kevin Grogan has been writing about pharmaceuticals for over twenty years in roles that have included online editor for PharmaTimes. After four years freelancing, which involved writing for all the principal titles in the sector, as well as consultancy work with major pharmaceutical companies, he joined Scrip as Managing Editor, Europe, Commercial in the summer of 2017.
Covering all aspects of the pharma industry, Kevin has interviewed pretty much all the leading figures in the sector, both in the UK and globally. A regular attendee at financial and medical conferences worldwide (and moderating at some), he has also appeared on BBC television and radio, ITV and Channel 4 to discuss events in the pharmaceutical industry.
Fluent in Spanish, he previously worked as a journalist on rock/pop music publications, was chief sub editor at the Catholic weekly newspaper The Universe and also contributed articles to the likes of The Independent and the Manchester Evening News on football.
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Kevin Grogan
The Danish group is beefing up its operations across the Atlantic as it prepares filings for dasiglucagon and glepaglutide.
Although far from a one-product company, data in Q4 will be key to whether the brittle bone drug could become a blockbuster for the UK NASDAQ-listed biotech.
The PAOLA-1 study has shown the benefit of Lynparza for ovarian cancer patients regardless of tumor mutation status which should firm up the drug's dominance in the PARP inhibitor space.
The Dementia Discovery Fund is backing the UCL spin-off's efforts to develop therapies that modulate astrocyte function.
The US FDA has issued a complete response letter for KPI-121 but Kala hopes to resubmit the drug during the first half of next year backed by data from the ongoing STRIDE 3 study.
Sales of injectable semaglutide shored up Novo's second quarter, but all eyes are on the expected launch of an oral version in the third quarter.